PDS Biotechnology Corporation (PDSB): History, Ownership, Mission, How It Works & Makes Money

Ever heard of PDS Biotechnology Corporation (PDSB) and wondered what they're all about? This clinical-stage biopharmaceutical company is making waves with its innovative immunotherapies for cancers and infectious diseases, utilizing their proprietary Versamune platform. With a recent market cap of $46.75 million and ongoing Phase 3 clinical trials, including the VERSATILE-003 trial for HPV16-positive head and neck cancer, what exactly does PDSB do and how does it plan to transform cancer treatment? Keep reading to discover the history, mission, and business model that drives this company forward.

PDS Biotechnology Corporation (PDSB) History

PDS Biotechnology Corporation Founding Timeline

Year established

PDS Biotechnology Corporation was founded in 2005.

Original location

The company is headquartered in Lawrenceville, New Jersey.

Founding team members

While specific details on all founding team members are not readily available in the search results, Dr. Frank Bedu-Addo is a key figure as the co-founder and CEO. His leadership has been instrumental since the company's inception.

Initial capital/funding

Information regarding the initial capital or funding at the company's founding is not available in the provided search results.

PDS Biotechnology Corporation Evolution Milestones

PDS Biotechnology Corporation Transformative Moments

• Versamune® Platform Development: The creation and advancement of the Versamune® platform stands as a cornerstone. This innovative technology enhances the body's ability to recognize and attack cancer cells, marking a significant advancement in cancer immunotherapy.
• Clinical Trial Outcomes: Positive results from Phase 2 and ongoing Phase 3 clinical trials for PDS0101 have validated the potential of the Versamune® platform. These outcomes have not only propelled the company forward but also attracted attention from investors and pharmaceutical partners.
• Regulatory Milestones: Achieving FDA Fast Track designation for PDS0101 underscored the urgent need for new treatments for HPV-positive cancers. This regulatory support has accelerated the development process and provided a pathway to potential market approval.
• Strategic Partnerships and Funding: Securing substantial funding through collaborations and private placements has enabled PDS Biotechnology to expand its research and development efforts. These partnerships are crucial for the company's long-term growth and success.

For detailed insights into the financial aspects, consider reading: Breaking Down PDS Biotechnology Corporation (PDSB) Financial Health: Key Insights for Investors

PDS Biotechnology Corporation (PDSB) Ownership Structure

Understanding PDS Biotechnology Corporation's ownership structure is crucial for investors and stakeholders, as it reveals the distribution of control and influence within the company. The ownership is distributed among institutional investors, individual shareholders, and company insiders.

PDS Biotechnology Corporation's Current Status

PDS Biotechnology Corporation is a publicly traded company, listed on the Nasdaq Capital Market under the ticker symbol PDSB. This means that its shares are available for purchase by the general public, and the company is subject to the regulations and reporting requirements of the U.S. Securities and Exchange Commission (SEC).

PDS Biotechnology Corporation's Ownership Breakdown

The ownership of PDS Biotechnology is distributed among various types of shareholders. Here's a breakdown:

PDS Biotechnology Corporation's Leadership

The leadership team is responsible for the strategic direction and operational management of PDS Biotechnology. Key members of the leadership team as of April 2025 include:

• Dr. Frank Bedu Addo: Chief Executive Officer.
• Gregory P. Conn: Chief Financial Officer.
• Dr. Lauren V. Wood: Chief Medical Officer.

These individuals play critical roles in guiding the company's research and development efforts, clinical trials, and overall business strategy.

To gain more insights into the dynamics of investor activity surrounding PDS Biotechnology, consider exploring: Exploring PDS Biotechnology Corporation (PDSB) Investor Profile: Who’s Buying and Why?

PDS Biotechnology Corporation (PDSB) Mission and Values

PDS Biotechnology Corporation focuses on developing targeted cancer immunotherapies, aiming to transform cancer treatment and improve patient outcomes through innovative approaches.

PDS Biotechnology Corporation's Core Purpose

Official mission statement

While an explicit, formally declared mission statement was not found in the provided search results, PDS Biotechnology's core purpose can be inferred from their activities and focus. Their mission is to develop novel cancer immunotherapies to treat various cancers and improve patient outcomes. This involves:

• Creating potent immunotherapies that harness the body's immune system to fight cancer.
• Developing a clinical pipeline of Versamune®-based immunotherapies targeting different cancers.
• Collaborating with research institutions and pharmaceutical companies to advance cancer treatment.
• Improving the quality of life for cancer patients by providing more effective and less toxic treatment options.

Vision statement

Similarly, a specific vision statement was not explicitly stated in the search results. However, PDS Biotechnology's vision can be understood as:

• Becoming a leader in the field of cancer immunotherapy.
• Transforming cancer from a life-threatening disease into a manageable condition.
• Establishing Versamune® as a foundational technology for cancer treatment.
• Expanding the application of their immunotherapies to a broader range of cancers and infectious diseases.

Company slogan/tagline

Based on the information available, PDS Biotechnology does not have a prominently advertised official slogan or tagline. Without an explicitly defined slogan, the essence of PDS Biotechnology's commitment can be captured by:

• 'Innovating Cancer Immunotherapy for a Healthier Future.'
• 'Targeting Cancer, Empowering Immunity.'
• 'Advancing the Fight Against Cancer Through Immunotherapy.'

To discover more about the company's mission and values, check this out: Mission Statement, Vision, & Core Values of PDS Biotechnology Corporation (PDSB).

PDS Biotechnology Corporation (PDSB) How It Works

PDS Biotechnology is a clinical-stage biopharmaceutical company that focuses on developing immunotherapies to treat cancer and infectious diseases, primarily utilizing its Versamune® T-cell activating technology platform.

PDS Biotechnology's Product/Service Portfolio

PDS Biotechnology's Operational Framework

PDS Biotechnology operates through a focused research and development model, concentrating on its Versamune® technology platform to create targeted immunotherapies. The company's operational framework involves several key stages:

• Research and Development: Investing in preclinical and clinical research to advance its product candidates.
• Clinical Trials: Conducting Phase 1, Phase 2, and Phase 3 clinical trials to evaluate the safety and efficacy of its immunotherapies.
• Manufacturing: Working with contract manufacturing organizations (CMOs) to produce its Versamune®-based products.
• Regulatory Affairs: Navigating the regulatory landscape to secure approvals from agencies like the FDA for its products.
• Partnerships: Collaborating with other pharmaceutical companies and research institutions to expand its pipeline and market reach.

These activities are supported by a robust intellectual property portfolio and a management team with expertise in immunotherapy and drug development. For insights into the company's guiding principles, you can explore: Mission Statement, Vision, & Core Values of PDS Biotechnology Corporation (PDSB).

PDS Biotechnology's Strategic Advantages

PDS Biotechnology's strategic advantages stem from its innovative technology platform and targeted approach to immunotherapy:

• Versamune® Technology: This proprietary platform enhances the body's T-cell response, potentially leading to more effective cancer and infectious disease treatments.
• Targeted Immunotherapy: PDS Biotech focuses on developing therapies that precisely target cancer cells, reducing potential side effects and improving patient outcomes.
• Clinical Pipeline: The company has a pipeline of product candidates in various stages of clinical development, providing multiple opportunities for growth and value creation.
• Strategic Partnerships: Collaborations with leading research institutions and pharmaceutical companies validate its technology and expand its development capabilities.
• Experienced Management Team: A team of experts in immunotherapy, drug development, and commercialization drives the company's strategic direction and operational execution.

PDS Biotechnology Corporation (PDSB) How It Makes Money

PDS Biotechnology Corporation is a clinical-stage immunotherapy company that primarily focuses on developing novel cancer therapies. The company generates revenue through strategic collaborations, licensing agreements, and government grants, as it advances its Versamune®-based products through clinical trials.

PDS Biotechnology Corporation's Revenue Breakdown

As a clinical-stage company, PDS Biotechnology does not currently have products on the market and therefore does not generate revenue from product sales. Its revenue streams are primarily derived from collaborative agreements and government grants.

PDS Biotechnology Corporation's Business Economics

The business economics of PDS Biotechnology are characterized by substantial research and development costs, typical of a biotechnology company in the clinical stage. Key aspects include:

• R&D Expenses: A significant portion of the company’s expenditure is allocated to research and development, particularly clinical trials for its Versamune® platform-based immunotherapies.
• Funding: The company relies on funding through a combination of sources, including:
  • Private placements
  • Public offerings
  • Collaboration agreements
  • Government grants
• Strategic Collaborations: Forming strategic alliances with other pharmaceutical companies or research institutions can provide both funding and expertise, helping to offset development costs and accelerate the clinical trial process.
• Intellectual Property: The value of PDS Biotechnology is heavily influenced by its intellectual property portfolio, particularly the patents protecting its Versamune® technology.

To get more insights about PDS Biotechnology Corporation, read this informative article: Exploring PDS Biotechnology Corporation (PDSB) Investor Profile: Who’s Buying and Why?

PDS Biotechnology Corporation's Financial Performance

Given that PDS Biotechnology is a clinical-stage company, traditional financial metrics should be viewed within the context of its developmental phase. Here are key considerations:

• Cash Runway: Monitoring the company's cash reserves and burn rate is crucial. This indicates how long the company can sustain operations before needing additional funding. As of the fiscal year 2024, PDS Biotechnology reported having sufficient cash to fund operations into 2026, based on current projections.
• Operating Expenses: Analysis of operating expenses, particularly R&D and administrative costs, provides insights into how efficiently the company is managing its resources.
• Net Loss: As a development-stage company, PDS Biotechnology is expected to incur net losses as it invests heavily in R&D. The size of these losses and the company's ability to manage them are important indicators.
• Milestone Payments: Future revenues are highly dependent on achieving milestones in their clinical trials and securing further collaboration agreements.
• Stock Performance: Monitoring the company's stock performance and trading volume can provide insights into investor confidence and market sentiment.

PDS Biotechnology Corporation (PDSB) Market Position & Future Outlook

PDS Biotechnology is striving to solidify its position in the competitive immunotherapy landscape, focusing on its Versamune® platform to develop novel cancer therapies. The company's future hinges on the successful clinical development and commercialization of its lead product candidates, particularly PDS0101, and strategic partnerships to expand its reach and capabilities. For detailed insights into the company's financials, see: Breaking Down PDS Biotechnology Corporation (PDSB) Financial Health: Key Insights for Investors

Competitive Landscape

Opportunities & Challenges

Industry Position

PDS Biotechnology operates within the highly competitive and rapidly evolving immuno-oncology market. Its industry standing can be described through the following points:

• Niche Player: PDSB occupies a niche position, focusing on leveraging its Versamune® platform to develop targeted immunotherapies.
• Technology Differentiation: The Versamune® platform aims to enhance T-cell activation and tumor infiltration, potentially offering advantages over existing therapies in specific cancer types.
• Partnerships: Strategic collaborations are crucial for PDSB to expand its reach and compete effectively with larger pharmaceutical companies.
• Clinical Development Stage: As of April 2025, PDSB is primarily a clinical-stage company, with its success heavily dependent on the outcomes of ongoing clinical trials.